The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes

被引:18
|
作者
Thomas, M. C. [1 ]
机构
[1] Monash Univ, Dept Diabet, Melbourne, Vic, Australia
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2022年 / 128卷
关键词
Diabetic complications; Type; 2; diabetes; Cardiovascular disease; Diabetic foot disease; Diabetic eye disease; Metabolic-associated fatty liver disease; Diabetic kidney disease; CHRONIC KIDNEY-DISEASE; RISK-FACTORS; HEART-FAILURE; SICK FAT; MELLITUS; MORTALITY; METAANALYSIS; PREVALENCE; ALBUMINURIA; OUTCOMES;
D O I
10.1016/j.metabol.2021.154961
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with an increased risk of cardiovascular disease, heart failure, chronic kidney disease, fatty liver disease, eye and foot disease. But equally, these conditions are associated with an increased risk of type 2 diabetes. Rather than being simply considered complications of diabetes, as exists within a 'pure' type 1 diabetes paradigm, both type 2 diabetes and its comorbidities are primarily caused by a failure to effi-ciently sequester excess energy leading to the accumulation of sick fat (adiposopathy). Type 2 diabetes is a symptom of a chronic disease complex, just as cardiovascular, renal, eye, foot and/or liver disease, are. In addition, each of these conditions feed forward so that dysfunction in one system accelerates dysfunction in another, partly through their shared pathogenesis and partly due dysfunction that follows in their wake. This review will explore the sticky, brittle conglomeration of CArdiac, Renal, Adipo-Metabolic, Eye and Liver disease (hereafter collectively known as CARAMEL disease) that is coincident in most patients with type 2 diabetes and contextualise the recent changes in diabetes guidelines that now specifically focus on identifying and aggressively managing these high-risk individuals with it. (c) 2021 Published by Elsevier Inc.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes
    Geng, Tingting
    Chen, Jun-Xiang
    Zhou, Yan-Feng
    Lu, Qi
    Wan, Zhenzhen
    Liu, Liegang
    Pan, An
    Liu, Gang
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (06) : E216 - E222
  • [42] Dietary Patterns and Cardiovascular Disease Risk in People with Type 2 Diabetes
    Herrera, M. Carolina Archundia
    Subhan, Fatheema B.
    Chan, Catherine B.
    CURRENT OBESITY REPORTS, 2017, 6 (04): : 405 - 413
  • [43] Microvascular disease and cardiovascular outcomes among individuals with type 2 diabetes
    Kaze, Arnaud D.
    Santhanam, Prasanna
    Erqou, Sebhat
    Bertoni, Alain G.
    Ahima, Rexford S.
    Echouffo-Tcheugui, Justin B.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 176
  • [44] Metabolic phenotypes and risk of end-stage kidney disease in patients with type 2 diabetes
    Zhao, Lijun
    Zou, Yutong
    Wu, Yucheng
    Cai, Linli
    Zhao, Yuancheng
    Wang, Yiting
    Xiao, Xiang
    Yang, Qing
    Yang, Jia
    Ren, Honghong
    Tong, Nanwei
    Liu, Fang
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [45] Type 2 diabetes and cardiovascular prevention: the dogmas disputed
    Giugliano, Dario
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Esposito, Katherine
    ENDOCRINE, 2018, 60 (02) : 224 - 228
  • [46] Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 study
    Rodriguez-Poncelas, Antonio
    Coll-De Tuero, Gabriel
    Turro-Garriga, Oriol
    Barrot-de la Puente, Joan
    Franch-Nadal, Josep
    Mundet-Tuduri, Xavier
    BMC NEPHROLOGY, 2014, 15
  • [47] Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines
    Stougaard, Elisabeth B.
    Rossing, Peter
    Cherney, David
    Vistisen, Dorte
    Persson, Frederik
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (08)
  • [48] Cardiovascular risk reduction in type 2 diabetes: What the non-specialist needs to know about current guidelines
    Weir, Matthew R.
    DIABETES OBESITY & METABOLISM, 2024, 26 : 14 - 24
  • [49] Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    Williams, David M.
    Nawaz, Asif
    Evans, Marc
    DIABETES THERAPY, 2020, 11 (02) : 369 - 386
  • [50] Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25)
    Yokoyama, H.
    Araki, S.
    Haneda, M.
    Matsushima, M.
    Kawai, K.
    Hirao, K.
    Oishi, M.
    Sugimoto, K.
    Sone, H.
    Maegawa, H.
    Kashiwagi, A.
    DIABETOLOGIA, 2012, 55 (07) : 1911 - 1918